Ironwood promotes Mark Currie to president of R&D

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.

Ironwood promotes Mark Currie to president of R&D

Ironwood Pharmaceuticals named Mark Currie senior vice president, chief scientific officer and president of R&D. Currie joined the company in 2002, serving as senior vice president, R&D and chief scientific officer. He directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor, and initiated, built and led discovery pharmacology at Monsanto. "Mark's outstanding contributions to Ironwood, including his expertise, leadership and superb judgment, are invaluable as we move our R&D efforts forward, growing our active pipeline and expanding our development efforts globally on behalf of our shareholders and the patients we aim to serve," said Peter Hecht, chief executive officer of Ironwood. Release

Mark Currie--Ironwood Pharmaceuticals
Currie will serve as VP, chief scientific officer and president of R&D.

Arie Belldegrun--Teva Pharmaceutical Industries
Belldegrun will serve on the board of directors.


GenVec President ($GNVC) and CEO Cynthia L. Collins joined the board of directors at BioHealth Innovation. BioHealth announced that founding board member Jerry Parrott stepped down. Release

Dave Pfanzelter has been appointed to PURE Bioscience's Board of Directors. Pfanzelter has been a member of PURE Bioscience's Advisory Panel since July 2012. Release

Bioanalytical Systems ($BASI) promoted Jacqueline Lemke to CEO. Lemke has served as interim president and CEO since July 2012 and was named CFO in April 2012. Release

Mickey Urdea has joined the Board of Directors at Pressure BioSciences. Urdea founded and is a managing partner for Halteres Associates, a biotechnology consulting firm. Release

Aratana Therapeutics has appointed Don Stitzenberg as vice president of manufacturing and Tammy Newbold as vice president of chemistry, manufacturing and controls. Prior to joining Aratana, Stitzenberg founded Carnegie Business Associates and Newbold founded Ceris Consulting. Release

John A. Rogers voluntarily resigned from cancer therapy biotech Helix BioPharma's Board of Directors. Release

Aragon Pharmaceuticals brought on Paul Cleveland as its chief financial officer and executive vice president. Cleveland was previously a chief operating officer at Mohr Davidow Ventures. Release

Depomed ($DEPO) appointed former ISTA Pharmaceuticals President and CEO Vicente Anido to its Board of Directors. Anido comes from Windamere Venture Partners, where he was a general partner. Release

OvaScienceSM appointed Grunenthal Group CEO Harald F. Stock to its Board of Directors. Release

Pain Therapeutics ($PTIE) brought on Saira Ramasastry as a member of its Board of Directors as an independent director. Ramasastry is the founder and managing partner of Life Sciences Advisory. Release

> Bach Pharma appointed Daniel Cato as president of the company. Cato is a director and the vice president of project operations for Cato Research, headquartered in Durham, NC. Release

> Aesica recruited Jarrett Palmer as operations director of its formulated products business unit business. Palmer has over 15 years of experience in senior leadership positions and has managed facilities for global CMOs including Catalent Pharma Solutions and Piramal Healthcare. Release

Ritter Pharmaceuticals has named Larry Good chief medical officer. Good, a fellow of the American College of Gastroenterology, joined Ritter Pharmaceuticals in 2012. Release

Adrian Adams, president and CEO of Auxilium Pharmaceuticals ($AUXL), joins its Board of Directors as chairman. He replaces Thomas Schreck, co-founder of AcelRx and board member. Release

Xenon Pharmaceuticals has appointed Gary J. Bridger executive vice president of research and development. Bridger has spent over 20 years in the life sciences industry including positions at Johnson Matthey, AnorMED and Genzyme. Release

> Receptos tapped Graham Cooper to serve as chief financial officer. Cooper joins the company after serving as chief financial officer of Geron ($GERN) and Orexigen Therapeutics ($OREX). Release


Teva ($TEVA) gave Arie Belldegrun a spot on its Board of Directors to fill a vacancy. His term will extend until Teva's 2013 annual shareholder meeting. Release

The Board of Directors at Mylan ($MYL) voted to appoint Melina Higgins and Rajiv Malik to the board. Higgins was formerly a partner at Goldman, Sachs, and Malik is Mylan's president. Release

> Onyx Pharmaceuticals ($ONXX) tapped Pablo J. Cagnoni to serve as executive vice president, Global Research & Development and Technical Operations, effective March 2013. Cagnoni was senior vice president and global head of clinical development of Novartis Oncology. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.